Literature DB >> 20394542

Comparing anatomical pattern of topical anti-glaucoma medications associated lacrimal obstruction with a control group.

Mohsen Bahmani Kashkouli1, Farzad Pakdel, Masih Hashemi, Mohammad Jafar Ghaempanah, Reza Rezaee, Reza Kaghaz-Kanani, Ali Ahadian.   

Abstract

PURPOSE: To compare the anatomical pattern of lacrimal drainage system obstruction (LDSO) associated with topical anti-glaucoma medications (AGM) with a control group.
METHODS: In a cross-sectional controlled study, case group included patients on topical anti-glaucoma medications and control group included patients with no history of glaucoma, free of ocular disease, and not using topical medications. Data recording, eye examination, and categorization of patients into case and control groups were performed by a senior ophthalmology resident. Diagnostic probing and irrigation test was performed by an oculoplastic surgeon who was masked to the patients' data. Chi-square (X(2)) and tests were used to assess the effect of sex and systemic diseases, as well as logistic regression analysis with intra-cluster correlation for the effect of topical anti-glaucoma medications on lacrimal drainage system, and then independent sample t-tests to compare the mean ages, plus the binary logistic regression test for the effect of increasing age on LDSO.
RESULTS: There were 128 eyes of 96 patients in the case and 277 eyes of 172 patients in the control group. Two groups were similar regarding to the age, sex, and associated systemic disorders (0.3<P<0.5). There was a significantly more LDSO in the case than control group (P = 0.008). Upper LDSO was observed in 76.92% (20/26) of the cases, and 37.5% (9/24) of the control group (P = 0.01). Nasolacrimal duct obstruction was also found in 19.23% of case group.
CONCLUSIONS: Although punctum and canaliculus are the main anatomical sites of LDSO associated with topical AGM, common canaliculus and nasolacrimal duct separately or in association with punctum and canaliculus may also be involved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20394542     DOI: 10.3109/01676830903324284

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  5 in total

1.  Risk Factors for Ocular Surface Disease in Tunisian Users of Preserved Antiglaucomatous Eye Drops.

Authors:  Houda Lajmi; Wassim Hmaied; Besma Ben Achour; Amin Zahaf
Journal:  J Curr Ophthalmol       Date:  2021-07-05

Review 2.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

3.  Assessment and management of proximal and incomplete symptomatic obstruction of the lacrimal drainage system.

Authors:  Mohsen Bahmani Kashkouli; Farzad Pakdel; Victoria Kiavash
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

4.  External Dacryocystorhinostomy: Characteristics and Surgical Outcomes in Patients with and without Previous Dacryocystitis.

Authors:  Gilad Rabina; Shani Golan; Meira Neudorfer; Igal Leibovitch
Journal:  J Ophthalmol       Date:  2013-12-18       Impact factor: 1.909

Review 5.  A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications.

Authors:  Xiaoyu Zhou; Xinyue Zhang; Dengming Zhou; Yang Zhao; Xuanchu Duan
Journal:  Ophthalmol Ther       Date:  2022-08-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.